Gibney Anthony S 4

4 · Aura Biosciences, Inc. · Filed Mar 3, 2026

AI-generated summary of this filing

Updated Mar 3, 2026

Aura (AURA) CFO Anthony Gibney Receives RSU Awards

What Happened

Anthony S. Gibney, Aura Biosciences' Chief Financial and Business Officer, was granted a total of 200,000 shares on 2026-03-02 through two awards: 71,245 RSUs and 128,755 derivative shares (award/option-like). Both awards show an acquisition price of $0 (they are compensation grants, not open-market purchases).

Key Details

Transaction date: 2026-03-02; Form 4 filed 2026-03-03 (timely filing).
Awards: 71,245 RSUs (acquisition code A) and 128,755 derivative award (code A, derivative).
Price/Value: $0 per share (grant of equity compensation).
Vesting (from filing footnotes):
- 71,245 RSUs: vest in four substantially equal annual installments beginning January 15, 2027, subject to continued service. (F1)
- 128,755 derivative award: 25% vest on February 1, 2027; remaining 75% vests pro rata over the following 36 months, subject to continued service. (F2)
Shares owned after transaction: not specified in the filing.

Context

These are compensation awards (RSUs/derivative awards) that vest over time and require continued service; they are not open-market buys or immediate sales and therefore reflect planned compensation rather than an immediate trading signal.
The awards were reported promptly (filed the next day), and no sales, exercises for cash, or tax-withholding transactions were reported in this filing.

Form 4

Period: 2026-03-02

See Remarks

Transactions

Award
Common Stock
[F1]
2026-03-02+71,245→ 278,178 total
Award
Stock Option (Right to Buy)
[F2]
2026-03-02+128,755→ 128,755 total
Exercise: $6.14Exp: 2036-03-02→ Common Stock (128,755 underlying)

Footnotes (2)

[F1]These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on January 15, 2027, subject to the Reporting Person's continued service as of each such vesting date.
[F2]The shares underlying this option vest as follows: 25% of the shares vest on February 1, 2027 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date.

Signature

/s/ Conor Kilroy, as Attorney-in-Fact|2026-03-03

1 file